Breakthrough discovery gives new hope for treating macular degeneration
Scientists have made a major breakthrough in understanding how prevent Age Related Macular Degeneration (AMD) by controlling an inflammatory factor in the body called inflammatory component IL-18.
The disease makes it difficult to see out of the center of the eye because it causes yellowish/white deposits in the middle of the retina, obscuring vision. The middle of the retina is called the macula.
There is no therapy to treat the disease once it happens. The deposits in the eye are characteristic of ‘dry macular degeneration’ that often progresses to “wet” macular degeneration.
Progression of dry to wet AMD causes blood vessels begin to proliferate underneath the retina, leading to blindness.
Symptoms of the eye disease, which should be evaluated immediately, include straight lines appearing wavy, objects look further away or closer than they are, and doorways may appear crooked.
Over 200,000 people in the United States are diagnosed with wet macular degeneration each year.
Risk factors for the disease include smoking, being over age 60, female and family history. Caucasians are more prone to AMD than are other ethnicities. Other risk factors include hypertension and obesity.
Dr Sarah Doyle and Dr Matthew Campbell from Trinity College Dublin have published their findings in the journal Nature Medicine that drusen – the yellow/white deposits that accumulate in the macula - can lead to the production of two inflammatory components termed IL-1beta and IL-18.
Component identified that prevents AMD progression
"Traditionally, inflammation in the retina or indeed the eye in general is not beneficial and is a pathological hallmark of many eye diseases, including AMD. However we have identified, that one inflammatory component termed IL-18 acts as a so-called anti-angiogenic factor, preventing the progression of wet AMD" says Dr. Campbell in a media release.
Doyle further explains, "The progression from "dry" to "wet" AMD appears to be mediated by the inflammatory component IL-18, our results directly suggest that controlling or indeed augmenting the levels of IL-18 in the retinas of patients with dry AMD could prevent the development of the wet form of disease, which leads us to an exciting new prospect for a novel therapy for AMD.”